stockrow
Friday 6 November 2026
Export CTOR’s income statement to Excel — free account
Citius Oncology, Inc.
CTOR Healthcare Drug Manufacturers Specialty & Generic
- EPS
- 0.00%
- Free cash flow
- 0.00%
- Total debt
- +79.3%
Quarter to June 2026, against a year earlier
0.50
0.00
0.00%
Follow CTOR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | 0 | 0 | 2 | (21) | (24) | (46) | +596.0% | ||||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | 0 | 0 | 2 | (21) | (25) | (46) | +603.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | 0.00 | 0.20 | 0.27 | (0.31) | (0.34) | (0.47) | n/m | ||||||
| Cash flow | — | — | — | — | — | 0.00 | (0.03) | (0.07) | 0.00 | (0.07) | (0.18) | n/m | ||||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | (0.07) | (0.08) | (0.12) | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0.00 | (0.03) | (0.07) | (0.07) | (0.15) | (0.30) | n/m | ||||||
| Book value | — | — | — | — | — | 0.00 | 0.19 | (0.22) | 0.68 | 0.61 | 0.37 | n/m | ||||||
| Shares, m | — | — | — | — | — | 8 | 2 | 9 | 68 | 73 | 92 | +73.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | 0 | (1) | 0 | (5) | (19) | n/m | |||||
| Capex | — | — | — | — | — | 0 | 0 | — | (5) | (6) | (13) | n/m | ||||||
| Free cash flow | — | — | — | — | — | 0 | 0 | (1) | (5) | (11) | (32) | n/m | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 0 | 0 | (2) | (22) | (22) | (16) | +582.8% | |||||
| Net debt | — | — | — | — | — | 0 | 0 | 0 | 4 | 9 | 4 | +191.1% | ||||||
| Shareholders’ equity | — | — | — | — | — | 0 | 0 | (2) | 46 | 45 | 40 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (15.98) | 1.11 | 4.02 | (26.94) | (26.72) | (45.20) | (10.7) pt | |||||
| ROIC | — | — | — | — | — | (5.23) | (153.31) | 0.00 | (25.45) | (27.10) | (67.15) | (21.9) pt | ||||||
| ROE | — | — | — | — | — | 0.00 | 220.56 | 20.55 | (95.80) | (54.42) | (126.58) | (54.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 2 | 2 | — | — | — | 0.0% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | — | — | — | n/m | ||||||
Negative figures in brackets.
estimates
Latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Citius Oncology, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CPIX Cumberland Pharmaceuticals Inc. | $75.1M | — (loss-making) | — (loss-making) | −98.46% (below 0%: shrinking) | n/m | −82.78% (below 0%: shrinking) | 100.00% | (1,898.20%) | Compare |
| TLPH Talphera, Inc. | $52.4M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −33.11% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CTOR Citius Oncology, Inc. | $46.5M | — (loss-making) | — | — | n/m | 0.00% | 67.07% | (583.53%) | |
| ZYBT Zhengye Biotechnology Holding Limited | $41.0M | — | — | — | — | −69.31% (below 0%: shrinking) | — | — | Compare |
| INCR InterCure Ltd. | $39.1M | 6.2× | — (loss-making) | −6.53% (below 0%: shrinking) | n/m | +389.50% (above 0%: growing) | 32.04% | 0.00% | Compare |
| SCYX SCYNEXIS, Inc. | $32.8M | — (loss-making) | — (loss-making) | −8.56% (below 0%: shrinking) | n/m | −98.60% (below 0%: shrinking) | 100.00% | (3,308.51%) | Compare |
| RMTI Rockwell Medical, Inc. | $30.6M | — (loss-making) | — (loss-making) | +10.63% (above 0%: growing) | n/m | −12.92% (below 0%: shrinking) | 18.24% | (5.97%) | Compare |
| IXHL Incannex Healthcare Inc. | $28.5M | — (loss-making) | — (loss-making) | −92.31% (below 0%: shrinking) | n/m | +327.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CPHI China Pharma Holdings, Inc. | $22.8M | — (loss-making) | — (loss-making) | −7.56% (below 0%: shrinking) | n/m | −113.57% (below 0%: shrinking) | 8.82% | (150.99%) | Compare |
| Median of peers | $35.9M | — | — | −8.56% | — | −51.21% | 100.00% | (5.97%) |
Pay and ownership Proxy statement filed 26 August 2026
Ownership
Directors and executive officers, together
9.82%
Citius Pharmaceuticals, Inc.
71.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement